COST-EFFECTIVENESS ANALYSIS OF SACUBITRIL/VALSARTAN COMPARED WITH STANDARD ACEI THERAPIES FOR HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION IN TAIWAN

被引：1
|
作者：
Fann, C. [1 ]
Chen, S. [2 ]
机构：
[1] Kainan Univ, Taoyuan, Taiwan
[2] Novartis Taiwan, Taipei, Taiwan
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1239
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV93
引用
收藏
页码：A617 / A617
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
    Sandhu, Alexander T.
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Pearson, Steven D.
    Heidenreich, Paul A.
    ANNALS OF INTERNAL MEDICINE, 2016, 165 (10) : 681 - +
  • [2] Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
    Krittayaphong, Rungroj
    Permsuwan, Unchalee
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2018, 18 (05) : 405 - 413
  • [3] Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
    Rungroj Krittayaphong
    Unchalee Permsuwan
    American Journal of Cardiovascular Drugs, 2018, 18 : 405 - 413
  • [4] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION IN SWEDEN
    Costa-Scharplatz, M.
    Lang, A.
    McMurray, J. J.
    Woodcock, F.
    Haroun, R.
    Johansson, D.
    Lund, L. H.
    VALUE IN HEALTH, 2016, 19 (07) : A650 - A651
  • [5] Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
    McMurray, John J. V.
    Trueman, David
    Hancock, Elizabeth
    Cowie, Martin R.
    Briggs, Andrew
    Taylor, Matthew
    Mumby-Croft, Juliet
    Woodcock, Fionn
    Lacey, Michael
    Haroun, Rola
    Deschaseaux, Celine
    HEART, 2018, 104 (12) : 1006 - 1013
  • [6] The cost-effectiveness of sacubitril/valsartan in chronic heart failure with reduced ejection fraction
    Mcmurray, J. J. V.
    Cowie, M. R.
    Briggs, A.
    Taylor, M.
    Hancock, E.
    Trueman, D. David
    Haroun, R.
    Deschaseaux, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 276 - 276
  • [7] Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
    Gaziano, Thomas A.
    Fonarow, Gregg C.
    Claggett, Brian
    Chan, Wing W.
    Deschaseaux-Voinet, Celine
    Turner, Stuart J.
    Rouleau, Jean L.
    Zile, Michael R.
    McMurray, John J. V.
    Solomon, Scott D.
    JAMA CARDIOLOGY, 2016, 1 (06) : 666 - 672
  • [8] Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal
    Borges, Margarida
    Afonso-Silva, Marta
    Laires, Pedro A.
    Gouveia, Miguel
    Alarcao, Joana
    Ascencao, Raquel
    Costa, Joao
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) : 199 - 205
  • [9] Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction
    Zanfina, Ademi
    Alena, Pfeil Ma
    Elizabeth, Hancock
    David, Trueman
    Rola, Haroun
    Celine, Deschaseaux
    Matthias, Schwenkglenks
    SWISS MEDICAL WEEKLY, 2017, 147
  • [10] Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Liang, Lin
    Wu, David Bin-Chia
    Aziz, Mohamed Ismail Abdul
    Wong, Raymond
    Sim, David
    Leong, Kui Toh Gerard
    Wei, Yong Quek
    Tan, Doreen
    Ng, Kwong
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (02) : 174 - 181
12345